These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 8413656

  • 1. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.
    Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM.
    Nature; 1993 Oct 21; 365(6448):762-4. PubMed ID: 8413656
    [Abstract] [Full Text] [Related]

  • 2. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.
    Circ Res; 2004 Oct 15; 95(8):789-97. PubMed ID: 15388641
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.
    Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM.
    Nature; 1991 Sep 19; 353(6341):265-7. PubMed ID: 1910153
    [Abstract] [Full Text] [Related]

  • 4. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
    Holvoet P, Danloy S, Deridder E, Lox M, Bernar H, Dhoest A, Collen D.
    J Clin Invest; 1998 Jul 15; 102(2):379-85. PubMed ID: 9664079
    [Abstract] [Full Text] [Related]

  • 5. Cholesterol homeostatic mechanisms in transgenic mice with altered expression of apoproteins A-I, A-II and A-IV.
    Kalopissis AD, Chambaz J.
    Int J Tissue React; 2000 Jul 15; 22(2-3):67-78. PubMed ID: 10937356
    [Abstract] [Full Text] [Related]

  • 6. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo.
    Rotllan N, Ribas V, Calpe-Berdiel L, Martín-Campos JM, Blanco-Vaca F, Escolà-Gil JC.
    Arterioscler Thromb Vasc Biol; 2005 Sep 15; 25(9):e128-32. PubMed ID: 15994442
    [Abstract] [Full Text] [Related]

  • 7. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.
    Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ.
    Science; 1993 Jul 23; 261(5120):469-72. PubMed ID: 8332912
    [Abstract] [Full Text] [Related]

  • 8. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
    Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L, Beaudet A, Chan L.
    Circulation; 2003 Jun 03; 107(21):2726-32. PubMed ID: 12742997
    [Abstract] [Full Text] [Related]

  • 9. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor.
    Moore RE, Kawashiri MA, Kitajima K, Secreto A, Millar JS, Pratico D, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2003 Oct 01; 23(10):1914-20. PubMed ID: 12933536
    [Abstract] [Full Text] [Related]

  • 10. Suppression of induced atherosclerosis in h-apo AI transgenic mice by overexpression of human apo AI in the aortic wall.
    Li H, Gu S, Cao X, Wang Z, She M.
    Chin Med J (Engl); 2000 Jul 01; 113(7):657-61. PubMed ID: 11776042
    [Abstract] [Full Text] [Related]

  • 11. [The effect of expressed human apolipoprotein AI on plasma high density lipoprotein level in transgenic mice].
    Li H, Gu S, She M.
    Zhonghua Yi Xue Za Zhi; 1998 Jul 01; 78(7):531-3. PubMed ID: 10923465
    [Abstract] [Full Text] [Related]

  • 12. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport.
    Castro G, Nihoul LP, Dengremont C, de Geitère C, Delfly B, Tailleux A, Fievet C, Duverger N, Denèfle P, Fruchart JC, Rubin EM.
    Biochemistry; 1997 Feb 25; 36(8):2243-9. PubMed ID: 9047326
    [Abstract] [Full Text] [Related]

  • 13. Identification of a sequence of apolipoprotein A-I associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A-I containing particles.
    Sviridov D, Pyle L, Fidge N.
    Biochemistry; 1996 Jan 09; 35(1):189-96. PubMed ID: 8555173
    [Abstract] [Full Text] [Related]

  • 14. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions.
    Hedrick CC, Castellani LW, Wong H, Lusis AJ.
    J Lipid Res; 2001 Apr 09; 42(4):563-70. PubMed ID: 11290828
    [Abstract] [Full Text] [Related]

  • 15. Concentrations of apolipoprotein AI, AII, and E in plasma and lipoprotein fractions of alcoholic patients: gender differences in the effects of alcohol.
    Lin RC, Miller BA, Kelly TJ.
    Hepatology; 1995 Apr 09; 21(4):942-9. PubMed ID: 7705804
    [Abstract] [Full Text] [Related]

  • 16. Apolipoprotein A-II: a protein in search of a function.
    Hedrick CC, Lusis AJ.
    Can J Cardiol; 1994 May 09; 10(4):453-9. PubMed ID: 8193990
    [Abstract] [Full Text] [Related]

  • 17. ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator.
    Kido T, Kondo K, Kurata H, Fujiwara Y, Urata T, Itakura H, Yokoyama S.
    Lipids Health Dis; 2017 Nov 29; 16(1):225. PubMed ID: 29187200
    [Abstract] [Full Text] [Related]

  • 18. Apolipoprotein A-I-containing lipoproteins, with or without apolipoprotein A-II, as progenitors of pre-beta high-density lipoprotein particles.
    Hennessy LK, Kunitake ST, Kane JP.
    Biochemistry; 1993 Jun 08; 32(22):5759-65. PubMed ID: 8504094
    [Abstract] [Full Text] [Related]

  • 19. [Advances in apolipoprotein A- I and it's anti-atherosclerosis properties].
    Li M, Liu ZM.
    Sheng Wu Gong Cheng Xue Bao; 2003 Jul 08; 19(4):387-91. PubMed ID: 15969051
    [Abstract] [Full Text] [Related]

  • 20. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
    Pérez-Méndez O, Duhal N, Lacroix B, Bonte JP, Fruchart JC, Luc G.
    Clin Chim Acta; 2006 Jun 08; 368(1-2):149-54. PubMed ID: 16487502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.